Evidence map›Paper›PMID 36676146›Full record

ReviewLife (Basel, Switzerland)2023

The Concept of Cancer Stem Cells: Elaborating on ALDH1B1 as an Emerging Marker of Cancer Progression.

Ilias Tsochantaridis, Angelos Roupas, Sofie Mohlin, Aglaia Pappa, Georgia-Persephoni Voulgaridou

Open access · goldAbstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. The Impact of Cancer Stem Cells in Colorectal Cancer.International journal of molecular sciences · 2024
    Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Ilias TsochantaridisDepartment of Molecular Biology & Genetics, Democritus University of Thrace, 68100 Alexandroupolis, Greece.ORCID 0000-0002-1607-7470
Angelos RoupasDepartment of Molecular Biology & Genetics, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Sofie MohlinDivision of Pediatrics, Clinical Sciences, Lund Stem Cell Center, Lund University Cancer Center, 22384 Lund, Sweden.ORCID 0000-0002-2458-3963
Aglaia PappaDepartment of Molecular Biology & Genetics, Democritus University of Thrace, 68100 Alexandroupolis, Greece.ORCID 0000-0003-0913-4315
Georgia-Persephoni VoulgaridouDepartment of Molecular Biology & Genetics, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Democritus University of Thrace · GRLund University · SE

Funding

"InTechThrace: Integrated Technologies in biomedical research: multilevel biomarker analysis in Thrace" (MIS Code 5047285), under the Operational Program "Competitiveness, Entrepreneur-ship & Innovation" (EPAnEK), co-funded by the European Regional Develo MIS Code 5047285
6 · The paper itself

Abstract

Cancer is a multifactorial, complex disease exhibiting extraordinary phenotypic plasticity and diversity. One of the greatest challenges in cancer treatment is intratumoral heterogeneity, which obstructs the efficient eradication of the tumor. Tumor heterogeneity is often associated with the presence of cancer stem cells (CSCs), a cancer cell sub-population possessing a panel of stem-like properties, such as a self-renewal ability and multipotency potential. CSCs are associated with enhanced chemoresistance due to the enhanced efflux of chemotherapeutic agents and the existence of powerful antioxidant and DNA damage repair mechanisms. The distinctive characteristics of CSCs make them ideal targets for clinical therapeutic approaches, and the identification of efficient and specific CSCs biomarkers is of utmost importance. Aldehyde dehydrogenases (ALDHs) comprise a wide superfamily of metabolic enzymes that, over the last years, have gained increasing attention due to their association with stem-related features in a wide panel of hematopoietic malignancies and solid cancers. Aldehyde dehydrogenase 1B1 (ALDH1B1) is an isoform that has been characterized as a marker of colon cancer progression, while various studies suggest its importance in additional malignancies. Here, we review the basic concepts related to CSCs and discuss the potential role of ALDH1B1 in cancer development and its contribution to the CSC phenotype.

Indexed as

aldehyde dehydrogenase 1B1aldehyde dehydrogenasesALDHscancercancer stem cellsCSCs

Identifiers

PMID36676146
PMCPMC9863106
OpenAlexW4313898790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.